T1	p 100 135	patients with early breast cancer :
T2	p 314 347	patients with early breast cancer
T3	i 25 48	dose-dense FEC regimens
T4	i 54 75	growth factor support
T5	i 243 278	epirubicin to adjuvant chemotherapy
T6	i 517 522	FEC )
T7	i 551 554	FEC
T8	i 618 621	FEC
T9	i 709 723	dose-dense FEC
T10	i 777 780	FEC
T11	i 791 794	FEC
T12	i 886 901	pegfilgrastim 6
T13	i 917 939	subcutaneous injection
T14	i 1124 1127	FEC
T15	i 1139 1142	FEC
T16	i 1179 1182	FEC
T17	i 1242 1245	FEC
T18	i 1524 1527	FEC
T19	i 1856 1870	dose-dense FEC
T20	i 1882 1885	FEC
T21	o 1317 1363	adverse events and personal/logistical reasons
T22	o 1439 1486	diarrhoea . Grade 3-4 haematological toxicities
T23	o 1555 1588	incidences of febrile neutropenia
T24	o 1624 1638	adverse events
T25	o 1657 1700	liver enzymes and gastrointestinal events ;
T26	o 1784 1839	serious adverse events ( vomiting and throat oedema ) .
T27	o 1989 2009	Grade 3-4 toxicity .